Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687446 | 0.85 | CYP2C19 (0.57) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL7056948 | 0.85 | CYP2C19 (0.57) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL295742 | 0.85 | CYP2C19 (0.57) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL6262957 | 0.84 | KIF11 (0.47) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL19130513 | 0.83 | CYP2C19 (0.46) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL8358159 | 0.82 | MAPT (0.45) | MAPTKMT2AHIF1ACYP1A2LMNA | |
| SCHEMBL8363409 | 0.82 | KCNN4 (0.52) | MAPTKMT2AKCNN4HTTKDM4E | |
| SCHEMBL5898523 | 0.82 | SMN1; SMN2 (0.40) | KMT2AKIF11SMN1; SMN2 | |
| SCHEMBL5898545 | 0.82 | MAPT (0.43) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL28833568 | 0.82 | SCN5A (0.50) | MAPTKMT2AKIF11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5463125-A | 3-hydroxy-3-phenylpentamide | SANDOVAL GUILLERMO C (MX) | 1995-10-31 | — | — | US | claimed |
| CN-113930351-B | Application of GGH gene in increasing yield of tocopherol, recombinant yarrowia lipolytica for high yield of tocotrienol and application of recombinant yarrowia lipolytica | 陕西海斯夫生物工程有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20060287397-A1 | Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity | MEZA TOLEDO SERGIO E | 2006-12-21 | — | — | US | disclosed |
| WO-1997023202-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5463125-A | 3-hydroxy-3-phenylpentamide | SANDOVAL GUILLERMO C (MX) | 1995-10-31 | — | — | US | disclosed |
| US-5463125-A | 3-hydroxy-3-phenylpentamide | SANDOVAL GUILLERMO C (MX) | 1995-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287397-A1 | Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity | GABRB2, HRH3, HRH4 | MAPT 2331/4885KMT2A 211/4885CYP2C19 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.